Clene Inc. Presentation at the 72nd Emerging Growth Conference FAQ
Summary
What is the Emerging Growth Conference?
The Emerging Growth Conference is an event hosted by EmergingGrowth.com, focusing on identifying companies with strong management teams, innovative products, and potential for long-term growth across various sectors.
When and where is Clene Inc. presenting at the conference?
Clene Inc. is scheduled to present on June 12, 2024, at 2:20 p.m. ET. The conference is hosted online by EmergingGrowth.com.
Who from Clene Inc. will be speaking at the conference?
Clene’s President and CEO Rob Etherington and CFO Morgan Brown will provide a keynote speech at the conference.
What does Clene Inc. specialize in?
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.
What is CNM-Au8®?
CNM-Au8® is an investigational first-in-class therapy by Clene Nanomedicine Inc. that targets mitochondrial function and the NAD pathway to improve central nervous system cells’ survival and function while reducing oxidative stress.
Where can I find more information about Clene Inc.?
For more information about Clene Inc., visit their official website at www.Clene.com or the InvestorBrandNetwork newsroom at https://ibn.fm/CLNN.
How can I watch Clene Inc.’s presentation at the conference?
Details on how to view Clene Inc.’s presentation can be found at the conference’s webcast link: Emerging Growth Conference Webcast.
What are the implications of Clene Inc.’s participation in the conference?
Clene Inc.’s participation highlights its innovative approach to treating neurodegenerative diseases and its potential for long-term growth, offering investors and the public insight into its strategies and developments.
Who should I contact for more information about the conference or Clene Inc.?
For more information, you can contact IBN (InvestorBrandNetwork) at 310.299.1717 or via email at Editor@InvestorBrandNetwork.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 129794